TY - JOUR
T1 - A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit
T2 - A systematic review and meta-analysis
AU - Kim, Yun Gi
AU - Suh, Jung Won
AU - Sibbing, Dirk
AU - Kastrati, Adnan
AU - Ko, Young Guk
AU - Jang, Yangsoo
AU - Cho, Young Seok
AU - Youn, Tae Jin
AU - Chae, In Ho
AU - Choi, Dong Ju
AU - Kim, Hyo Soo
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background VerifyNow P2Y12 assay is used widely to evaluate residual platelet reactivity in patients taking P2Y12 receptor antagonists. However, a laboratory association between VerifyNow P2Y12 reaction unit (PRU) and hemoglobin, which might lead to wrong interpretation of the data, is reported. We performed these systematic review and meta-analysis to clearly define the relationship between PRU and hemoglobin and to elucidate whether the relationship, if any, is a true biological association or is just a laboratory error. Methods Through a comprehensive electronic and manual search, 10 studies were selected for the cohort level meta-analysis. Among 10 studies, we were able to retrieve the raw data of 5 studies, and a patient-level meta-analysis was performed. Potential publication bias was searched by funnel plot analysis and was actively adjusted, if present, by trim and fill method. Results The pooled analysis revealed a significant inverse correlation between PRU and hemoglobin (r = −0.349; P < .001; 10 studies with 4,793 patients). VerifyNow P2Y12 base unit, which reflects off-drug platelet reactivity, was also inversely correlated with hemoglobin (r = −0.526; P < .001; 8 studies with 4,395 patients). % Inhibition (r = 0.081; P = .059; 6 studies with 3,832 patients) and ΔPRU (r = −0.037; P = .188; 5 studies with 3,521 patients) were not associated with hemoglobin. A significant inverse association between PRU and hemoglobin was also observed in the patient-level meta-analysis (3,533 patients pooled from 5 studies; r = −0.335; P < .001). Light transmission aggregometry (r = 0.160; P = .072; 4 studies with 1,144 patients) and multiple electrode platelet aggregometry (r = −0.029; P = .394; 3 studies with 7,645 patients) showed no significant association with hemoglobin. Conclusions A significant inverse association was observed between PRU and hemoglobin which is likely to be a laboratory error. Clinicians should be aware that this association might lead to wrong interpretation of the data.
AB - Background VerifyNow P2Y12 assay is used widely to evaluate residual platelet reactivity in patients taking P2Y12 receptor antagonists. However, a laboratory association between VerifyNow P2Y12 reaction unit (PRU) and hemoglobin, which might lead to wrong interpretation of the data, is reported. We performed these systematic review and meta-analysis to clearly define the relationship between PRU and hemoglobin and to elucidate whether the relationship, if any, is a true biological association or is just a laboratory error. Methods Through a comprehensive electronic and manual search, 10 studies were selected for the cohort level meta-analysis. Among 10 studies, we were able to retrieve the raw data of 5 studies, and a patient-level meta-analysis was performed. Potential publication bias was searched by funnel plot analysis and was actively adjusted, if present, by trim and fill method. Results The pooled analysis revealed a significant inverse correlation between PRU and hemoglobin (r = −0.349; P < .001; 10 studies with 4,793 patients). VerifyNow P2Y12 base unit, which reflects off-drug platelet reactivity, was also inversely correlated with hemoglobin (r = −0.526; P < .001; 8 studies with 4,395 patients). % Inhibition (r = 0.081; P = .059; 6 studies with 3,832 patients) and ΔPRU (r = −0.037; P = .188; 5 studies with 3,521 patients) were not associated with hemoglobin. A significant inverse association between PRU and hemoglobin was also observed in the patient-level meta-analysis (3,533 patients pooled from 5 studies; r = −0.335; P < .001). Light transmission aggregometry (r = 0.160; P = .072; 4 studies with 1,144 patients) and multiple electrode platelet aggregometry (r = −0.029; P = .394; 3 studies with 7,645 patients) showed no significant association with hemoglobin. Conclusions A significant inverse association was observed between PRU and hemoglobin which is likely to be a laboratory error. Clinicians should be aware that this association might lead to wrong interpretation of the data.
UR - http://www.scopus.com/inward/record.url?scp=85016066754&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2017.03.006
DO - 10.1016/j.ahj.2017.03.006
M3 - Article
C2 - 28577681
AN - SCOPUS:85016066754
SN - 0002-8703
VL - 188
SP - 53
EP - 64
JO - American Heart Journal
JF - American Heart Journal
ER -